journal article·2025-11-05Open access

Hyaluronic Acid Microplates for Intra-articular Lubrication and Cartilage Protection in Post-traumatic Osteoarthritis

Agnese Fragassi, Antonietta Greco, Megan Keech, Amelia Soltes, Fang Yu, Sayanti Brahmachari, Roberto Palomba, Martina di Francesco, Miguel Echanove Gonzalez De Anleo, Froilan Granero-Molto, Luca Ceseracciu, Veronica Papa, Luca Goldoni, Aiman Abu Ammar, Richard D’Arcy, Haytam Kasem, Craig Duvall, Paolo Decuzzi

ACS Applied Materials & Interfaces· Volume 17· Issue 44

Abstract

High Resolution Image Download MS PowerPoint Slide Osteoarthritis (OA) is the most common joint disorder, characterized by a vicious cycle of synovial inflammation and cartilage degradation. Intra-articular injection of hyaluronic acid (HA)-based products, one of the currently available treatments, provides only temporary symptomatic relief without addressing the underlying inflammation. Here, we engineered several configurations of 20 × 5 μm square-shaped HA-based hydrogel microparticles (μHA) by photopolymerizing HA–methacrylate chains within a sacrificial template. The μHA mechano-pharmacological properties were tuned by adjusting the HA concentration, molecular weight, and degree of methacrylation, resulting in microparticles with a Young’s modulus ranging from a few tens (30 kPa) to a few hundred (200 kPa) kilopascals; a structure stable for over a month under oxidative stress conditions; and reduced friction in simulated synovial fluids. Under H 2 O 2 -induced oxidative conditions, μHA decreased the production of proinflammatory cytokines (IL-6, IL-1β, and TNF-α) in human chondrocytes to basal levels. In a three-dimensional OA cartilage model, μHA reduced glycosaminoglycan release and matrix metalloproteinase-13 activity, demonstrating chondroprotective effects. In a rigorous murine model of early-stage post-traumatic OA, a single intra-articular injection of μHA lowered proinflammatory gene expression in the synovium to basal levels. In summary, μHA offers a drug-free approach to managing OA by enhancing lubrication and reducing inflammation, providing a sustained therapeutic activity over several weeks.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Osteoarthritis Treatment and Mechanisms · Proteoglycans and glycosaminoglycans research · Total Knee Arthroplasty Outcomes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, Genova 16163, Italy

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, Padova 35131, Italy

Department of Medicine and Surgery, nanomedicine Center (NANOMIB), University of Milano-Bicocca, Via Follereau 3, Vedano Al Lambro 20854, Italy

Department of Biomedical Engineering, Vanderbilt University, 2301 Vanderbilt Place, Nashville, Tennessee 37235-1631, United States

Cell Therapy Area, Clínica Universidad de Navarra, Av. de Pío XII, 36, Pamplona, Navarra 31008, Spain

Materials Characterization Facility, Istituto Italiano di Tecnologia, Via Morego 30, Genova 16163, Italy

Department of Pharmaceutical Engineering

Azrieli College of Engineering Jerusalem

Chemical Engineering, School of Engineering of Matter, Transport and Energy

Arizona State University

Biotribology Inter-Disciplinary Research Center, Azrieli College of Engineering Jerusalem, 26 Yaakov Shreibom Street, Ramat Beit Hakerem, Jerusalem 9103501, Israel

Department of Medicine, Division of Oncology, Stanford University School of Medicine, 269 Campus Drive, Stanford, California 94305, United States

Funding

H2020 Marie Sklodowska-Curie Actions · National Institute of Arthritis and Musculoskeletal and Skin Diseases

References (50)

Show source-provided references
1. 10.1016/j.joca.2012.11.01210.1016/j.joca.2012.11.012 ↗
2. 10.1038/nrdp.2016.7210.1038/nrdp.2016.72 ↗
3. 10.1172/JCI9514710.1172/JCI95147 ↗
4. 10.1016/S2665-9913(24)00117-610.1016/S2665-9913(24)00117-6 ↗
5. 10.1016/j.bonr.2023.10165810.1016/j.bonr.2023.101658 ↗
6. 10.1038/nrrheum.2014.4410.1038/nrrheum.2014.44 ↗
7. 10.1016/j.joca.2019.06.01110.1016/j.joca.2019.06.011 ↗
8. 10.3390/molecules2620612210.3390/molecules26206122 ↗
9. 10.1002/art.3445310.1002/art.34453 ↗
10. 10.1126/science.aay827610.1126/science.aay8276 ↗
11. 10.1038/nmat404810.1038/nmat4048 ↗
12. 10.1002/jor.2579310.1002/jor.25793 ↗
13. 10.1016/j.actbio.2017.06.04310.1016/j.actbio.2017.06.043 ↗
14. 10.3233/BIR-1510410.3233/BIR-15104 ↗
15. 10.1177/194760351774991910.1177/1947603517749919 ↗
16. 10.3390/cells906132810.3390/cells9061328 ↗
17. 10.1371/journal.pone.012519210.1371/journal.pone.0125192 ↗
18. 10.1002/jor.2428110.1002/jor.24281 ↗
19. 10.1016/j.bbadis.2016.01.00310.1016/j.bbadis.2016.01.003 ↗
20. 10.1007/s40744-014-0001-810.1007/s40744-014-0001-8 ↗
21. 10.1177/1947603523115453010.1177/19476035231154530 ↗
22. 10.3390/jcm1208298210.3390/jcm12082982 ↗
23. 10.1021/acsnano.2c0639310.1021/acsnano.2c06393 ↗
24. 10.1002/wnan.178010.1002/wnan.1780 ↗
25. 10.1002/adfm.20240154710.1002/adfm.202401547 ↗
26. 10.3390/jox1403007210.3390/jox14030072 ↗
27. 10.1021/acsami.1c0208210.1021/acsami.1c02082 ↗
28. 10.1016/j.jconrel.2017.03.01410.1016/j.jconrel.2017.03.014 ↗
29. 10.1111/j.2042-7158.1987.tb06268.x10.1111/j.2042-7158.1987.tb06268.x ↗
30. 10.1016/j.ijpharm.2015.12.01510.1016/j.ijpharm.2015.12.015 ↗
31. 10.1021/acsnano.1c0400510.1021/acsnano.1c04005 ↗
32. 10.1016/j.jconrel.2019.12.03910.1016/j.jconrel.2019.12.039 ↗
33. 10.1007/s40544-023-0794-y10.1007/s40544-023-0794-y ↗
34. 10.3390/molecules2519440710.3390/molecules25194407 ↗
35. 10.1136/ard-2022-22277310.1136/ard-2022-222773 ↗
36. 10.1038/s41551-021-00780-310.1038/s41551-021-00780-3 ↗
37. 10.1002/art.2776510.1002/art.27765 ↗
38. 10.1002/art.3837510.1002/art.38375 ↗
39. 10.1016/j.biomaterials.2007.11.04710.1016/j.biomaterials.2007.11.047 ↗
40. 10.1021/bm049508a10.1021/bm049508a ↗
41. 10.1016/j.jbiomech.2007.06.00210.1016/j.jbiomech.2007.06.002 ↗
42. 10.1002/smll.20200451910.1002/smll.202004519 ↗
43. 10.1126/sciadv.abl644910.1126/sciadv.abl6449 ↗
44. 10.1016/j.bioactmat.2021.03.02210.1016/j.bioactmat.2021.03.022 ↗
45. 10.1007/s10439-010-0167-310.1007/s10439-010-0167-3 ↗
46. 10.1016/j.cellsig.2018.10.00510.1016/j.cellsig.2018.10.005 ↗
47. 10.1016/j.ejpb.2014.10.01610.1016/j.ejpb.2014.10.016 ↗
48. 10.3389/fphar.2024.148803610.3389/fphar.2024.1488036 ↗
49. 10.1002/btm2.1047510.1002/btm2.10475 ↗
50. 10.1111/jcmm.1520410.1111/jcmm.15204 ↗